Preliminary experience with inhaled milrinone in cardiac surgery.
Yoan Lamarche, Louis P Perrault, Simon Maltais...
https://pubmed.ncbi.nlm.nih.gov/17400468/Actively Recruiting
Led by Montreal Heart Institute · Updated on 2026-06-25
141
Participants Needed
1
Research Sites
30 weeks
Total Duration
This research focuses on patients undergoing cardiac surgery with cardiopulmonary bypass CPB who have pulmonary hypertension PH or right ventricular dysfunction. The study is a randomized, double-blind, controlled clinical trial evaluating whether inhaled epoprostenol combined with milrinone can improve outcomes during the transition off CPB. Pulmonary hypertension and right ventricular dysfunction are linked to increased risks such as longer mechanical ventilation, extended hospital stays, and higher mortality, making improved management important. Participants will be randomly assigned to receive either a combination of inhaled epoprostenol and milrinone or a placebo before the start of CPB. The inhaled treatments are delivered via an ultrasonic nebulizer over 20 minutes. The experimental group receives 4mg of milrinone and 60 mcg of epoprostenol, while the control group receives saline. The study aims to compare the rate of difficult CPB weaning, defined by the need for inotropes, vasopressors, mechanical support, or return to bypass. During the trial, patients will be monitored for hemodynamic stability and clinical outcomes including vasopressor and inotrope use, duration of organ dysfunction, and length of ICU stay. Various hemodynamic parameters and postoperative complications will be assessed for up to one year. The total participant involvement covers the perioperative and postoperative period to evaluate the impact of the inhaled combination therapy on cardiac surgery recovery.
CONDITIONS
Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation
S
Stephanie Jarry, PhD (c)
A
André Denault, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Montreal Heart Institute
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 20 minutes
Participants receive either inhaled milrinone and epoprostenol or a placebo via nebulizer before starting cardiopulmonary bypass during cardiac surgery.
1 treatment session before surgery
Duration - Up to 1 year
Participants are monitored for heart function, use of supportive medications, organ function, and recovery outcomes after surgery for up to one year.
Regular assessments during hospital stay and follow-up visits
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yoan Lamarche, Louis P Perrault, Simon Maltais...
https://pubmed.ncbi.nlm.nih.gov/17400468/François Haddad, André Y Denault, Pierre Couture...
https://pubmed.ncbi.nlm.nih.gov/17566702/Jeremy B Green, Brendon Hart, Elyse M Cornett...
https://pubmed.ncbi.nlm.nih.gov/28526144/André Y Denault, Jean S Bussières, Ramiro Arellano...
https://pubmed.ncbi.nlm.nih.gov/27470232/J F Hardy, S Belisle
https://pubmed.ncbi.nlm.nih.gov/8103681/Reem M Haj, J Erric Cinco, C David Mazer
https://pubmed.ncbi.nlm.nih.gov/16547439/Michael G Gaies, James G Gurney, Alberta H Yen...
https://pubmed.ncbi.nlm.nih.gov/19794327/Naushad Hirani, Nathan W Brunner, Ali Kapasi...
https://pubmed.ncbi.nlm.nih.gov/32682511/P V van Heerden, N M Gibbs, N Michalopoulos
https://pubmed.ncbi.nlm.nih.gov/9288373/David M Shahian, Sean M O'Brien, Giovanni Filardo...
https://pubmed.ncbi.nlm.nih.gov/19559822/Montreal Heart Institute
Lead Sponsor